Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label Phase II Study in anti-GBM disease (Goodpasture's disease) with Adverse Renal Prognosis to Evaluate the Efficacy and Safety of IdeS --GOOD-IDES Etude de phase II multicentrique, en ouverte, afin d'évaluer l'efficacité et la tolérance des IdeS dans la glomérulonéphrite anti-MBG (syndrome de Goodpasture) avec atteinte rénale sévère. GOOD-IdeS.

Next Previous
Trial Profile

An Open-Label Phase II Study in anti-GBM disease (Goodpasture's disease) with Adverse Renal Prognosis to Evaluate the Efficacy and Safety of IdeS --GOOD-IDES Etude de phase II multicentrique, en ouverte, afin d'évaluer l'efficacité et la tolérance des IdeS dans la glomérulonéphrite anti-MBG (syndrome de Goodpasture) avec atteinte rénale sévère. GOOD-IdeS.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 21 Apr 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Imlifidase (Primary) ; Corticosteroids; Cyclophosphamide
  • Indications Anti-glomerular basement membrane disease
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms GOOD-IDES

Most Recent Events

  • 21 Apr 2022 New trial record
  • 01 Apr 2022 Results published in the Journal of the American Society of Nephrology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top